AKB

Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column at TIDES USA

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Other Science, Other Technology, Medical Devices, Research, Genetics, Science, Safety, AKBA, EVP, RNA, Hynes Convention Center, DNA, ACS, Therapy, Booth, Nucleotide, Multimedia, AKB, Fine chemical

This new synthesis column offers drastically reduced changeover time between batches while maintaining user safety and product quality.

Key Points: 
  • This new synthesis column offers drastically reduced changeover time between batches while maintaining user safety and product quality.
  • View the full release here: https://www.businesswire.com/news/home/20240502639431/en/
    Concept image of the THESYS™ ACS ERGO synthesis column.
  • (Photo: Business Wire)
    Following the success of AKB’s DAC ERGO™, a liquid chromatography column, the company has continued advancing column technology with the THESYS™ ACS ERGO.
  • The THESYS ACS ERGO is designed for oligonucleotide synthesis and includes an operator-friendly design to facilitate a smooth and safe changeover between runs.

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

Retrieved on: 
Thursday, April 11, 2024
Research, Pharmaceutical, Oncology, Infectious Diseases, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Genetics, Science, Biotechnology, Manufacturing, Health, Cancer, Cell biology, Marketing, DSM-IV codes, Partnership, Therapy, SVP, Patient, Gene expression, Multimedia, AKB, GMP, Quality of life, Viral, Fine chemical

Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.

Key Points: 
  • Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.
  • This cooperation aims to accelerate the development and commercialization of oligonucleotide-based therapies to improve quality of life for patients worldwide.
  • View the full release here: https://www.businesswire.com/news/home/20240411168939/en/
    Asahi Kasei Bioprocess' and Axolabs' equipment.
  • To meet the escalating demand for oligonucleotide therapeutics, Axolabs, a CRDMO providing drug substances for oligonucleotide-based therapeutics, is establishing a new GMP manufacturing hub in Berlin.

Asahi Kasei Bioprocess’ Massachusetts Training Center Expands 2024 Course Offerings for Career Development and Industry Training

Retrieved on: 
Tuesday, April 2, 2024
Chemicals, Plastics, Alternative Energy, Energy, Manufacturing, Continuing, Pharmaceutical, Education, Training, General Health, Infectious Diseases, Science, Biotechnology, Health, Engineering, Research, AKB, Supervisor, Learning, Pfizer, MTC, Conceptual, Technical, Travel, Student, Multimedia, Tutoring

Asahi Kasei Bioprocess’ (AKB) Massachusetts Training Center has announced an expansion of 2024 class offerings designed for individuals across various stages of their careers.

Key Points: 
  • Asahi Kasei Bioprocess’ (AKB) Massachusetts Training Center has announced an expansion of 2024 class offerings designed for individuals across various stages of their careers.
  • Courses will cover a range of topics, including, but not limited to, bioprocess overview, pathogen safety, and virus removal filter operators' training.
  • View the full release here: https://www.businesswire.com/news/home/20240402865162/en/
    Asahi Kasei Bioprocess' Massachusetts Training Center.
  • In addition, Asahi Kasei is open to feedback to improve the sessions,” said Kyle Eichelmann, Sales Manager at Texcell, when asked about his experience with the MTC program.